(Q77206225)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9728898%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

title

Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9728898%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference

1 reference

1 reference

T Kantola

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9728898%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

K T Kivistö

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9728898%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

P J Neuvonen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9728898%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

publication date

1 August 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9728898%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

3 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9728898%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9728898%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

page(s)

177-182

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9728898%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9728898%20AND%20SRC:MED&resulttype=core&format=json

Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole

3 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

Drug-interaction-induced rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

A potentially hazardous interaction between erythromycin and midazolam.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

Dose of midazolam should be reduced during diltiazem and verapamil treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

Determination of erythromycin base and 2'-acetylerythromycin in human plasma using high-performance liquid chromatography with electrochemical detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

Diltiazem enhances the effects of triazolam by inhibiting its metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990151-5

10.1016/S0009-9236(98)90151-5

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9728898%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference